BioSpace News Archive

Science 37, the industry leader in virtual clinical trials, announced today that Mike Zaranek has joined the company as its chief financial officer (CFO). He will oversee all aspects of finance, accounting, and

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its investigational small-molecule pyruvate kinase M2 isoform

Duchesnay USA, a pharmaceutical company dedicated to women’s health, and PlushCare, a virtual health platform are announcing that women who are experiencing menopause symptoms can now request a virtual appointment with an independent healthcare provider via the PlushCare platform through osphena.com.

Acquisition to expand global footprint, enhance product development and broaden Adaptas’ scientific instrument industry leadership position

BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company committed to developing first-in-class, curative immuno-oncology therapeutics, today announced that it has established operations at a new corporate headquarters and laboratory facilities at the Open Medicine Institute (OMI) Colla

Funding Will Accelerate the Development of ChromaCode Assays for Infectious Disease, Targeted Toward Resource-Limited Communities Worldwide

Accuray Incorporated (NASDAQ: ARAY) today announced that MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, has selected the Accuray Synchrony® Real-time Adaptive Technology

Siren, a medical device company that has developed breakthrough technology to embed microsensors within fabric, allowing for mass production of affordable, washable smart textiles with remote patient monitoring applications, announced the appointment of David Castiglioni as Chief Commercial Officer.

Cochlear received FDA approval to lower the age of implantation at the beginning of COVID-19 crisis; earlier access to cochlear implantation for children provides opportunity for better hearing, speech and language outcomes in children born deaf

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be participating in the Maxim Group and M-Vest COVID-19 Virtual Conference Series: The Role of Cell Therapy and Clarity on Testing on May 27, 2020 at 10:00 am Eastern Time. Interested investors